Back
Larimar Therapeutics, Inc. Stock Predictions
The Next Gold Rush
DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at
Buy
53
LRMR
Larimar Therapeutics, Inc.
Last Price:
$3.33
Seasonality Move:
40.5%
7 Day Trial
ALL ACCESS PASS
$
7
Exxon and Chevron Have an Unlikely New Competitor
DISCLOSURE: EnergyX's Regulation A offering has been qualified by the SEC. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available atLarimar Therapeutics, Inc. Stock Forecast
-
Is Larimar Therapeutics, Inc. Stock Undervalued?The current Larimar Therapeutics, Inc. [LRMR] share price is $3.33. The Score for LRMR is 53, which is 6% above its historic median score of 50, and infers lower risk than normal.
-
LRMR is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
Will Larimar Therapeutics, Inc. Stock Go Up Next Year?
Data Unavailable
Larimar Therapeutics, Inc. Stock Rating
Data Unavailable
Larimar Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
larimartx.com
52-Week Data
52-Week High:
5.37
52-Week Low:
1.61
Prediction Charts
Market Cap:
285M
Price in USD:
3.33
Volume:
734K
Beta:
0.65
Technical Analysis
SMA50:
3.67
SMA100:
3.90
SMA200:
3.30
52-Wk Change:
-12.14%
Stock Predictions
-
Is Larimar Therapeutics, Inc. stock public?Yes, Larimar Therapeutics, Inc. is a publicly traded company.
-
What is the Larimar Therapeutics, Inc. stock quote today?The Larimar Therapeutics, Inc. stock price is 3.33 USD today.
-
How to buy Larimar Therapeutics, Inc. stock online?You can buy Larimar Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Dec-18 | 3.50 | 3.43 | 3.61 | 3.38 |
| Dec-19 | 3.42 | 3.65 | 3.73 | 3.38 |
| Dec-22 | 3.64 | 4.00 | 4.05 | 3.55 |
| Dec-23 | 3.96 | 3.91 | 3.96 | 3.79 |
| Dec-24 | 3.91 | 3.97 | 4.04 | 3.90 |
| Dec-26 | 3.95 | 3.93 | 4.00 | 3.86 |
| Dec-29 | 3.89 | 3.96 | 4.01 | 3.86 |
| Dec-30 | 3.98 | 3.91 | 3.98 | 3.85 |
| Dec-31 | 3.89 | 3.81 | 3.94 | 3.72 |
| Jan-5 | 3.49 | 3.36 | 3.52 | 3.31 |
| Jan-6 | 3.36 | 3.37 | 3.46 | 3.35 |
| Jan-7 | 3.37 | 3.42 | 3.52 | 3.31 |
| Jan-8 | 3.39 | 3.36 | 3.45 | 3.34 |
| Jan-9 | 3.40 | 3.33 | 3.50 | 3.31 |
Larimar Therapeutics, Inc. Earnings
Data Unavailable
Larimar Therapeutics, Inc. Forecast Revenue Growth
Data Unavailable
-
Analysts estimate an earnings increase this quarter of $0.02 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.17 per share, and a decrease next year of $0.05 per share.
* Larimar Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.